Importantly, lower levels of XBP1s, ATF4, and BiP expression in pre-treatment tumor biopsy samples significantly correlated with better treatment responses and prolonged survival in different groups of melanoma patients undergoing anti-CTLA-4 therapy [193]. The gene discussed is ATF4; the disease is melanoma.